key: cord-0873039-wt53iqpq
authors: Kim, Eun Jin; Choi, Sun Ha; Park, Jae Seok; Kwon, Yong Shik; Lee, Jaehee; Kim, Yeonjae; Lee, Shin Yup; Choi, Eun Young
title: Use of Darunavir-Cobicistat as a Treatment Option for Critically Ill Patients with SARS-CoV-2 Infection
date: 2020-09-01
journal: Yonsei Med J
DOI: 10.3349/ymj.2020.61.9.826
sha: 66c2e2174676f918a30e601d12371a00baf22338
doc_id: 873039
cord_uid: wt53iqpq

We retrospectively reviewed patients with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections who were admitted to an intensive care unit in Daegu, South Korea. The outcomes of patients who did (cases) or did not (controls) receive darunavir-cobicistat (800–150 mg) therapy were compared. Fourteen patients received darunavir-cobicistat treatment, and 96 received other antiviral therapy (controls). Overall, the darunavir-cobicistat group comprised patients with milder illness, and the crude mortality rate of all patients in the darunavir-cobicistat group was lower than that in the controls [odds ratio (OR) 0.20, 95% confidence interval (CI) 0.04–0.89, p=0.035]. After 1:2 propensity-score matching, there were 14 patients in the darunavir-cobicistat group, and 28 patients in the controls. In propensity score-matched analysis, the darunavir-cobicistat group had lower mortality than the controls (OR 0.07, 95% CI 0.01–0.52, p=0.009). In conclusion, darunavir-cobicistat therapy was found to be associated with a significant survival benefit in critically ill patients with SARS-CoV-2 infection.

seven tertiary or referral hospitals in Daegu, South Korea between February 18 and April 5, 2020. A WHO guidance document defines laboratory confirmation of SARS-CoV-2 infection as a positive result of a real-time reverse transcriptase-polymerase chain reaction assay of samples obtained from nasal and pharyngeal swabs. The first part of this study was a retrospective cohort study that included all patients who were critically ill with laboratory-confirmed SARS-CoV-2 infection. Cobicistat-boosted darunavir was assigned to patients who failed other antiviral treatments or at the physician's discretion. The outcomes of patients who did (cases) or did not (controls) receive darunavir-cobicistat (800-150 mg) therapy were compared. The second part of the investigation comprised a matched (1:2) case-control study, with the patients who did or did not receive darunavir-cobicistat therapy designated as "cases" and "controls" (Fig. 1) , respectively. This study was conducted in accordance with the tenets of the Declaration of Helsinki and was reviewed and approved by the Institutional Review Board at each hospital. The requirement for informed consent was waived because of the retrospective study design (IRB Number: YUH IRB 2020-03-057, IRB Institution: Yeungnam University Medical Center).

The present study included 110 critically ill patients who received intensive care for COVID-19, of whom 14 received darunavir-cobicistat treatment and 96 received other antiviral therapy.

There were no significant intergroup differences with regard to age, sex ratio, body mass index, and underlying disease/conditions between the groups who did and did not receive darunavir-cobicistat treatment (Table 1) Scores [median score 6 (IQR 5-7) vs. 8 (IQR 5-11), p<0.001] were significantly lower in the darunavir-cobicistat group than in the controls, indicating that the darunavir-cobicistat group had patients with milder illness. The incidence of shock and acute respiratory distress syndrome (ARDS) during hospitalization did not differ between the two groups. There were no between-group differences in the length of ICU stay or survival, although the number of deaths was significantly lower in the darunavir-cobicistat treatment group (14.3% vs. 46.9%, p=0.021). There were also significant differences in the numbers of patients who survived and were discharged from the ICU: 10 (83.3%) in the darunavir-cobicistat group and 29 (39.2%) in the controls (p=0.004). The crude mortality rates of all patients and ARDS patients in the darunavir-cobicistat group were lower than those in the controls [odds ratio (OR) 0.20, 95% confidence interval (CI) 0.04-0.89, p=0.035 and OR 0.17, 95% CI 0.04-0.79, p=0.024, respectively) ( Table 2 ). Mortality rates after adjusting for variables, such as age ≥65 years and SOFA score, were the same in both groups. Two variables, age ≥65 years and SOFA score, were selected for propensity-score matching based on outcomes of the univariate and multivariate analyses. After 1:2 propensity-score matching, there were 14 patients in the darunavir-cobicistat group and 28 in the controls. Table 1 shows the patient characteristics for both groups after matching the propensity scores; the two groups were balanced. The number of deaths was significantly lower in the darunavir-cobicistat group (14.3% vs. 50.0%, p= 0.025). In the propensity score-matched analysis, the darunavircobicistat group had lower mortality than the controls (OR 0.09, 95% CI 0.01-0.52, p=0.009) ( Table 2) . Furthermore, the darunavir-cobicistat group, which comprised ARDS patients, had lower mortality than the controls (OR 0.08, 95% CI 0.01-0.50, p=0.008).

To determine the effect of darunavir-cobicistat on COVID-19, Fig. 1 . Schematic representation of the data analysis plan for the cohort study and the matched case-control study. *Adjusted aged ≥65 years, Sequential Organ Failure Assessment. OR, odds ratio; CI, confidence interval. 0.025 DRV-COBI, darunavir-cobicistat; APACHE, Acute Physiology and Chronic Health Evaluation; SOFA, Sequential Organ Failure Assessment; NEWS, National Early Warning Scores; PaO2, Partial pressure of oxygen in the arterial blood; FiO2, percentage of inspired oxygen; ECMO, extracorporeal membrane oxygenation; ICU, intensive care unit; NA, not applicable. Data are presented as a median (interquartile range) or n%. *p value of DRV-COBI treatment vs. no DRV-COBI treatment, before matching, † p value of DRV-COBI treatment vs. no DRV-COBI treatment, after matching.

we subjected the matched cohorts to Kaplan-Meier analysis and noted a significant between-group difference in in-hospital survival rate (p=0.048, respectively) (Fig. 2) .

To our knowledge, this is the first report to evaluate the treatment effect of darunavir-cobicistat in critically ill COVID-19 patients in whom darunavir-cobicistat therapy was associated with a significant survival benefit over standard treatment.

The mechanism of action underlying the effect of darunavircobicistat on SARS-CoV-2 remains to be elucidated. Several studies have evaluated the therapeutic effects of antiretroviral drugs in COVID-19, although the results are controversial. A recent randomised clinical trial by Cao, et al. 8 investigated the efficacy of lopinavir-ritonavir (400-100 mg, twice daily for 14 days) treatment in COVID-19 and showed no beneficial effect thereof over standard care in hospitalised adults with severe COVID-19. Regarding antiviral therapy with darunavir-cobicistat, there are no human clinical data on the use of this drug combination in COVID-19 patients, although a randomised clinical trial of darunavir-cobicistat is ongoing in China (NCT04252274).

This study has several limitations. First, because the study was retrospective, the possibility of selection bias cannot be excluded. Second, the propensity score matching method is limited because it adjusted only for observed covariates. Finally, there was a selection bias of using cobicistat-boosted darunavir only in 14 patients with physician preference and interference with other antiviral agents. Owing to this limitation, the conclusions of nonrandomised studies that use propensity scores must be assessed for consistency with other results, as well as for biological plausibility. Therefore, we suggest that preclinical studies and prospective clinical studies are needed to confirm these preliminary results.

In conclusion, darunavir-cobicistat therapy was associated with a significant survival benefit in critically ill patients with SARS-CoV-2 infection in this study. Further study of darunavircobicistat in relation to this highly virulent disease is needed. 

Role of lopinavir/ritonavir in the treatment of SARS: initial virological and clinical findings

Abidol and darunavir can effectively inhibit coronavirus

Discovering drugs to treat coronavirus disease 2019 (COVID-19)

Pharmacologic treatments for coronavirus disease 2019 (COVID-19): a review

Rezolsta ® (darunavir/cobicistat): first boosted protease inhibitor co-formulated with cobicistat

Rationale and clinical utility of the darunavir-cobicistat combination in the treatment of HIV/AIDS

Data on the stability of darunavir/cobicistat suspension after tablet manipulation

A trial of lopinavir-ritonavir in adults hospitalized with severe Covid-19